The inverse relationship between plasma HDL-cholesterol (HDL-C) levels and atherosclerotic cardiovascular disease (CVD) provides the epidemiological basis for the widely accepted hypothesis that HDL is atheroprotective. Despite intense research, the underlying mechanisms of HDL atheroprotection remain incompletely understood. Indeed, recent clinical trials (1, 2) indicate the complexity of HDL physiology and the challenges in developing HDL therapies. HDL function, and benefit with a specific therapy, may depend more on the molecular mechanism driving increases in HDL-C than on the absolute level of HDL-C (3). Some interventions that raise HDL-C levels may have no benefit and even promote atherosclerosis (4), while other therapies may reduce CVD without actually changing HDL-C levels (1). Overall, the epidemiological evidence suggests that the majority of mechanisms that result in higher HDL-C levels in vivo will provide atheroprotection; the question is how to identify such targets. This requires a shift in mindset toward assessing HDL in terms of its atheroprotective functions rather than just levels of cholesterol and its main apoprotein, APOAI.
Proposed mechanisms of HDL atheroprotection
Experimental studies, including limited work in humans, suggest several distinct but potentially overlapping HDL atheroprotective functions. These include reverse cholesterol transport (RCT) (5) and reductions in oxidative stress and in innate immune inflammation (6, 7).
RCT. The ability of HDL to promote RCT has been thought of as the major function of HDL for more than four decades (8, 9) , although convincing demonstration of this process in vivo has only emerged in the past few years (5) . In atherosclerosis the primary cell that is loaded with cholesterol is the arterial macrophage - therefore, it may make more sense to conceptualize RCT in terms of macrophage cholesterol efflux potential or "macrophage RCT" rather than in terms of total peripheral tissue cholesterol RCT (5, 9) .
The first step in macrophage RCT is efflux of cholesterol from arterial macrophages, a highly regulated process involving specific transporters including ABC transporter A1 (ABCA1) and ABCG1 (5). ABCA1 facilitates efflux of cholesterol and phospholipids (including oxidized phospholipids) to lipid-poor APOAI, whereas ABCG1-mediated cholesterol efflux to more mature HDL particles (10) is enhanced by lecithin:cholesterol acyltransferase (LCAT) and APOE in HDL (11) and may be in part be responsible for the "passive cholesterol efflux" characterized by Rothblat, Phillips, and coworkers (12) . Expression of both transporters is upregulated in macrophages by oxysterols that activate the nuclear hormone receptor liver X receptors (LXRs) and directly target the promoters of theses genes. Macrophage expression of both ABCA1 and ABCG1 enhances macrophage cholesterol efflux and protects against experimental atherosclerosis.
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receptor BI (SR-BI), or indirectly by cholesterol ester (CE) transfer protein-driven (CETP-driven) CE transfer to apoB lipoproteins and liver uptake (5) . Hepatic SR-BI mediates selective uptake of HDL-CE and free cholesterol without concomitant uptake of HDL protein (4). Despite reducing plasma HDL-C levels, hepatic SR-BI overexpression in mice enhances macrophage RCT and reduces atherosclerosis (4, 5) . The role of SR-B1 in human physiology remains uncertain, however, because relatively little HDL-CE is taken up directly by the liver in humans (13) .
CETP mediates the exchange of HDL-CE for triglyceride on apoB lipoproteins. CETPdeficient humans have extremely high HDL-C levels and slow turnover of APOAI; however, the role of CETP in RCT and atherosclerosis remains uncertain (3, 5, 14) . Pharmacological inhibition of CETP results in increased levels of large HDL particles (15) . It is possible that inhibition of CETP results in a switch from an ABCA1-to an ABCG1-mediated cholesterol efflux pathway (10, 11). At present, it is unclear what might be the optimal level of CETP inhibition for increasing macrophage cholesterol efflux. Also, the failure of the CETP inhibitor torcetrapib in the ILLUMINATE (Investigation of Lipid Level Management to Understand Its Impact in ATherosclerotic Events) trial likely involved non-HDL-related toxicity, such as off-target hypertensive side effects (2). It will be interesting to see whether changes in HDL levels, subclasses, or function were predictive of the outcome in the ILLUMI-NATE study or whether CETP inhibition promotes or retards novel measures of RCT in experimental models. However, the failure of torcetrapib in the ILLUMINATE study dramatically illustrates the need for plasma or other surrogate biomarkers that faithfully reflect the underlying antiatherogenic properties of HDL.
Antiinflammatory and antioxidant effects of HDL. A body of literature has emerged supporting specific antiinflammatory and antioxidant effects of HDL (6, 7). Remarkably, in this issue of the JCI, Vaisar and colleagues (16), using a proteomics approach, found that more HDL proteins are involved in immune/inflammatory functions (23 of 48 proteins) than in lipid transport and metabolism (22 proteins), suggesting a fundamental role for HDL in innate immunity. Indeed, HDL binds to and modulates the actions of endotoxin and other bacterial antigens, provides a platform for assembly of innate immune complexes, acts as an acceptor for oxidized phospholipids, and blocks oxidation of apoB lipoproteins (6, 7, 17, 18) . HDL levels fall during acute inflammation, perhaps to achieve conditions permissive for acute inflammation. Two independent proteomic analyses have revealed HDL enrichment in proteins regulating complement, proteolysis, and coagulation (16, 19) , suggesting modulation of inflammation-induced tissue injury and hemostasis. The recovery of HDL levels following the acute inflammatory response could play an important role in suppressing ongoing inflammation.
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lipase A 2 (Lp-PLA 2 ), promote catabolism of oxidized phospholipids. Accumulation of oxidized lipids, however, negatively regulates the activities of these enzymes. Using cell-based assays of monocyte chemotactic activity or cell-free assays of oxidation, Fogelman and colleagues have shown that HDL particles isolated during the acute phase and from patients with coronary artery disease (CAD) fail to retard, and in fact enhance, LDL-mediated inflammation (7) . Notably, a convergence of HDL antiinflammatory functions with its RCT functions has emerged - HDL isolated from CAD patients contains a specific myeloperoxidase-driven tyrosine modification of APOAI that coincides with attenuation of cholesterol efflux via ABCA1 (20, 21) .
Measures of HDL atheroprotective function and the HDL proteome
We continue to have limited insight into the precise mechanisms of HDL atheroprotection, in part, due to our inability to assess HDL functions in vivo. Although several measures of HDL particles, composition, and function exist (Table 1) , there are no tractable methods for assessing RCT in humans, and simple, reliable, and reproducible assays of HDL antiinflammatory functions are lacking. In this setting, recent HDL proteomic studies may provide novel insights into HDL physiology and the potential for development of bioassays of HDL function, although such studies are in their infancy (16, 19, (22) (23) (24) . In this issue, Vaisar et al. present the largest and most comprehensive mass spectrometry-based study to date of the HDL proteome (16) . Arguably, the most striking aspect of these early studies is not just the diversity of the HDL proteins and peptides (16, 19) identified but also the overrepresentation of proteins involved in several non-lipid transport functions, including the acutephase response, complement regulation, proteolysis, and coagulation (16, 19, 22, 24) (Supplemental Table 1 ; supplemental material available online with this article; doi:10.1172/JCI31608DS1), suggesting novel HDL functions. Although convincing evidence of functional roles for HDL in these processes is limited, past and emerging studies have shown that HDL and/or APOAI can attenuate response to experimental endotoxemia (17) , inhibit complement activation (25) , and inhibit platelet activation, serpins, and thrombosis (26) .
The current study (16) is notable for examining a large human sample (albeit including only 33 subjects), comparing HDL proteins isolated from the plasma of healthy controls with HDL proteins from patients with CAD (n = 7) and with HDL isolated from human atherosclerotic plaques. Importantly, semiquantitative peptide counting linked to appropriate statistical methodologies was applied to assess relative protein abundance and provided evidence that HDL in CAD is enriched in APOE and complement components 3 and 4, protein changes that may relate to both RCT and antiinflammatory functions. The observation that the plasma HDL in CAD contains a subset of proteins found on HDL in atherosclerotic plaques requires validation but implies that the HDL proteome can provide a window into plaque activity. Whether such protein changes, and which ones, are measures of HDL atheroprotective functions has yet to be determined.
The degree of variation across studies in the number and identity of proteins associated with HDL (Supplemental Table 1 ; refs. 16, 19, [22] [23] [24] raises some concerns. This is likely related to technical differences in HDL isolation and subsequent methodology and highlights the need for technical standardization and rigorous external validation.
Future directions
In moving forward, the challenge will be to develop relatively simple HDL biomarkers that can be measured before and after a clinical intervention, then correlated with clinical outcomes or atherosclerosis imaging, and ultimately used in CVD risk prediction. Examples could be an immunoassay for the content of specific proteins in HDL or its subfractions; e.g., the proportion of HDL or subclasses containing APOE, LCAT, or Lp-PLA 2 , specific complement proteins, antiproteases, or oxidized lipids could turn out to have predictive value. While more complicated measurements, such as macrophage RCT or even cell-based assays of macrophage cholesterol efflux using HDL isolated before and after intervention, are less likely to be applicable on a large scale or validated against clinical outcomes, they may be critical for proof of concept of novel therapies and understanding the functional properties of simpler HDL biomarkers. Application of a broad spectrum of assays that address HDL functionality as well as composition is likely to provide the greatest insight into the relationship between HDL and atherosclerosis and the effects of novel therapies. Indeed, failure to apply such measures as a complement to atherosclerosis imaging will reduce the likelihood of developing HDL-related prognostic and therapeutic strategies.
